2023
Biological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapy
2015
Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single‐centre experience
Atzmony L, Amitay-Laish I, Gurion R, Shahal-Zimra Y, Hodak E. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single‐centre experience. Journal Of The European Academy Of Dermatology And Venereology 2015, 29: 2382-2389. PMID: 26299651, DOI: 10.1111/jdv.13243.Peer-Reviewed Original ResearchConceptsExtracorporeal photopheresisErythrodermic mycosis fungoidesSezary syndromeLeukaemic involvementMycosis fungoidesErythrodermic MFTreated with extracorporeal photopheresisBlood responseNarrow-band ultraviolet BSkin responsePatch-stage MFClinical response rateElectron beam radiotherapyTopical nitrogen mustardTertiary medical centreMultimodal approachBeam radiotherapyMultimodality regimenClinical responseAdjunctive therapyInterferon-aSurvival advantageMedical filesPhotopheresisPatients